{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:51:14Z","timestamp":1790175074986,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,12,16]],"date-time":"2009-12-16T00:00:00Z","timestamp":1260921600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> Prophylaxis with concentrates of factor VIII has become the standard of care for patients with severe haemophilia A because of its ability to prevent joint and other bleeding events. Recent evidence suggests that the prophylactic use of bypassing therapy \u2013 activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) \u2013 provides similar benefits to haemophilia patients with inhibitors. To assess the efficacy and safety of prophylaxis with the aPCC FEIBA, a meta\u2010analysis was conducted of six studies and a total of 34 inhibitor patients. The mean prophylactic dose was 78.5\u2003U\u2003kg<jats:sup>\u22121<\/jats:sup>, typically infused three to four times weekly. A total of 31 of 33 patients (94%) for whom bleeding data were available prior to prophylaxis experienced a decrease in the rate of haemorrhage, albeit minor in some patients, and, regardless of the type of haemorrhage measured, had on average a 63.9% reduction in bleeding episodes during FEIBA prophylaxis. In the three studies that specifically assessed all joint bleeding, the 18 patients evaluated experienced an average reduction in annual joint bleeding of 74% while on prophylactic regimens. Among the four patients in this group who received concurrent immune tolerance induction and the 14 patients treated with prophylaxis only, annual joint bleeding decreased by an average of 79% and 78%, respectively. Anamnesis following FEIBA exposure was observed in some patients but had no impact on prophylactic efficacy. No thrombotic or other complications were reported. These results suggest that the prophylactic administration of FEIBA can be an effective and safe method for reducing bleeding events in patients with haemophilia A and inhibitors.<\/jats:p>","DOI":"10.1111\/j.1365-2516.2009.02126.x","type":"journal-article","created":{"date-parts":[[2009,12,16]],"date-time":"2009-12-16T19:53:16Z","timestamp":1260993196000},"page":"263-271","source":"Crossref","is-referenced-by-count":42,"title":["Assessing the benefits of FEIBA prophylaxis in haemophilia patients with inhibitors"],"prefix":"10.1111","volume":"16","author":[{"given":"L. A.","family":"VALENTINO","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,2,25]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470757260.ch7"},{"key":"e_1_2_8_3_2","volume-title":"Treatment of Hemophilia","author":"Kasper CK"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20162"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00939.x"},{"key":"e_1_2_8_7_2","first-page":"255","article-title":"Human coagulation factor FVIIa (recombinant) in the management of limb\u2010threatening bleeds unresponsive to alternative therapies: results from the NovoSeven\u00ae emergency\u2010use programme in patients with severe haemophilia or with acquired inhibitors","volume":"11","author":"Arkin S","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615357"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615388"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1990.30790385521.x"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1656122"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200060030-00003"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00993.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00034.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01204.x"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1997.130135000.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00695.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb00815.x"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1992.tb00546.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00757.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000208615"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02580.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00789.x"},{"key":"e_1_2_8_25_2","volume-title":"[Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding)","author":"MASAC"},{"key":"e_1_2_8_26_2","first-page":"691","article-title":"Modern treatment of haemophilia","volume":"73","author":"Berntorp E","year":"1995","journal-title":"Bull World Health Organ"},{"key":"e_1_2_8_27_2","volume-title":"WFH Guidelines for the Management of Hemophilia","author":"Srivastava A"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2008.01960.x"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01442.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1055\/s-0037-1616550","article-title":"Effective prophylaxis with daily recombinant factor VIIa (rFVIIa\u2010Novoseven) in a child with high titre inhibitors and a target joint","volume":"86","author":"Saxon BR","year":"2001","journal-title":"Thromb Haemost"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01096.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02663.x"},{"key":"e_1_2_8_33_2","first-page":"266a","article-title":"Factor VIII inhibitor bypass activity (FEIBA) for prophylaxis during immune tolerance induction (ITI) in patients with high\u2010responding inhibitors [abstract]","volume":"96","author":"Kreuz W","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_34_2","first-page":"265a","article-title":"Efficacy and safety of factor VIII inhibitor bypass activity (FEIBA) for long\u2010term prophylaxis in patients with high\u2010responding inhibitors [abstract]","volume":"96","author":"Kreuz W","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00771.x"},{"issue":"1","key":"e_1_2_8_36_2","article-title":"Long\u2010term prophylaxis with FEIBA\u00ae in patients with high\u2010responding inhibitors","volume":"1","author":"Ettingshausen CE","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"2","key":"e_1_2_8_37_2","article-title":"Can long term prophylaxis with APCC improve the bleeding rate and quality of life of frequently bleeding haemophiliacs with inhibitor?","volume":"12","author":"Lambert T","year":"2006","journal-title":"Haemophilia"},{"issue":"2","key":"e_1_2_8_38_2","article-title":"FEIBA prophylaxis in hemophilia A patient with inhibitors decrease bleeding episodes, maintain arthropathy and enhance quality of life","volume":"12","author":"Cheng S\u2010N","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01284.x"},{"key":"e_1_2_8_40_2","unstructured":"EwingN DeGuzmanC PullensL.Anamnesis in patients with hemophilia and inhibitors who receive activated prothrombin complex concentrates for prophylaxis. Poster presented at the XXIst Congress of the International Society of Thrombosis and Haemostasis; July 6\u201312 2007 Geneva Switzerland 2007."},{"key":"e_1_2_8_41_2","doi-asserted-by":"crossref","unstructured":"Escuriola EttingshausenC KreuzW.Early long\u2010term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction. A prospective clinical case series.Haemophilia2009(in press).","DOI":"10.1111\/j.1365-2516.2009.02116.x"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)90871-6"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01346.x"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200403000-00001"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06359.x"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01497.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056710"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612943"},{"key":"e_1_2_8_49_2","first-page":"45","article-title":"The German Registry of immune tolerance treatment in hemophilia \u2013 1999 update","volume":"85","author":"Lenk H","year":"2000","journal-title":"Haematologica"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00469.x"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1159\/000071637"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2004.00944.x"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00532.x"},{"issue":"2","key":"e_1_2_8_54_2","article-title":"Evaluating the safety profile of factor eight inhibitor bypassing activity (FEIBA)","volume":"14","author":"Adams J","year":"2008","journal-title":"Haemophilia"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00626.x"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V61.1.36.36"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470987124.ch13"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2025"},{"key":"e_1_2_8_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000006.pub3"},{"key":"e_1_2_8_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00161-4"},{"key":"e_1_2_8_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)00024-X"},{"key":"e_1_2_8_62_2","unstructured":"PRO\u2010FEIBA.A prospective randomized cross\u2010over study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia A and inhibitors. Available at:http:\/\/www.clinicaltrial.gov\/ct\/show\/NCT00221195?order=6. Accessed May 28 2008."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2009.02126.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2516.2009.02126.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:37:45Z","timestamp":1698683865000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2009.02126.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,25]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1365-2516.2009.02126.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2009.02126.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,25]]}}}